Alan Health Technologies Inc. dba Alan
FDA issued a warning letter to Alan Health Technologies Inc. dba Alan (Brooklyn, NY) on February 20, 2026, after reviewing the company's website alanmeds.com in December 2025. The agency found that Alan's website displayed compounded semaglutide and tirzepatide products with the 'Alan' brand name on the pictured labels, falsely implying Alan was the compounder of those drugs when it was not. This constitutes misbranding under FDCA sections 502(a) and 502(bb), and the introduction of these products into interstate commerce violates section 301(a). Alan was given 15 working days to respond with corrective steps, and failure to comply could result in seizure or injunction.
Flagged claims (1)
The compounded semaglutide and tirzepatide products displayed on your website identify "Alan" on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not.
Required actions (3)
Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.
Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].
Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most pharmacy / compounding sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker